The positive X-TOLE2 data and near-term NDA submission are the primary catalysts, but the revenue decline and increased losses temper the bullish case. Traders should monitor enrollment updates for X-TOLE3 and X-ACKT studies, and any regulatory feedback ahead of the NDA filing.
Price Chart
Executive Summary
Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in Q1 2025, with zero revenue compared to $7.5M a year ago. The miss is overshadowed by positive Phase 3 X-TOLE2 data for azetukalner in focal onset seizures, with an NDA submission expected in Q3 2026 and a strong cash position of $1.34B funding operations into 2029.
Key Financial Metrics
Key Facts
- Phase 3 X-TOLE2 study met primary endpoint with placebo-adjusted median percent change in seizure frequency of -42.7% (25 mg dose), the highest ever observed in a pivotal FOS study.
- NDA submission for azetukalner in focal onset seizures planned for Q3 2026.
- Cash, cash equivalents and marketable securities of $1,339.6 million as of March 31, 2026, up from $586.0 million at year-end 2025.
- Net loss increased to $102.3 million in Q1 2026 from $65.0 million in Q1 2025, driven by higher R&D spend and zero collaboration revenue.
- Research and development expenses rose to $88.5 million from $61.2 million year-over-year.
Financial Impact
Net loss of $102.3M in Q1 2026, up from $65.0M in Q1 2025; revenue declined from $7.5M to $0.
Risk Factors
- Regulatory delays or negative FDA review of the NDA for azetukalner.
- Clinical trial setbacks in ongoing Phase 3 studies for MDD, BPD, or PGTCS.
- Dilution risk from continued use of ATM or follow-on offerings despite strong cash position.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290503 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 2, 2026 13w ago | Press Release | $60.96 $64.19 | ▲ +5.30% | ▲ +5.71% | $38.02 (−37.63%) |
Jun 5, 2026 17w ago | 144 | $51.21 $60.54 | ▲ +18.22% | ▲ +16.59% | $38.02 (−25.76%) |
Jun 3, 2026 17w ago | 8-K | $52.99 $60.96 | ▲ +15.04% | ▲ +16.41% | $38.02 (−28.25%) |
May 7, 2026 21w ago | Press Release | $56.44 $51.73 | ▼ −8.35% | ▼ −8.37% | $38.02 (−32.64%) |
Apr 22, 2026 23w ago | DEFA14A | $55.41 $54.68 | ▼ −1.32% | ▼ −5.95% | $38.02 (−31.38%) |
Apr 19, 2026 23w ago | Press Release | $57.09 $53.71 | ▼ −5.92% | ▼ −10.12% | $38.02 (−33.40%) |
Apr 15, 2026 24w ago | Press Release | $58.88 $55.00 | ▲ +6.59% | ▲ +12.63% | $38.02 (+35.43%) |
Apr 13, 2026 24w ago | 8-K | $59.35 $55.78 | ▼ −6.02% | ▼ −12.31% | $38.02 (−35.94%) |
Apr 7, 2026 25w ago | Press Release | $57.65 $57.40 | ▲ +0.43% | ▲ +10.21% | $38.02 (+34.05%) |
Mar 13, 2026 29w ago | Insider Cluster | $55.23 $58.60 | ▼ −6.10% | ▼ −2.51% | $38.02 (+31.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access